KRAS and colorectal cancer: Another G12C inhibitor, adagrasib (MRTX849), with demonstrated activity in KRAS G12C-mutated NSCLC and colorectal cancer (CRC), has recently shown effectiveness in PDAC and other solid tumors (NCT03785249) [37].